A Trial of the effect of tolvaptan on patients with nephrotic state and chronic heart failure

A Trial of the effect of tolvaptan on patients with nephrotic state and chronic heart failure - a trial of tolvaptan on nephrotic state

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011763

Enrollment

Registered

2013-11-27

Start date

2013-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nephrotic syndrome with heart failure

Interventions

tolvaptan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: objects must meet every criteria 1. who have heart failure with diuresis 2. who have edema and nephrotic syndrome *the definition of nephrotic syndrome (1) urinary protein >3.5g/day continues (2) serum protein <= 6.0g/dl (or serum albumin <= 3.0g/dl) 3. inpatient

Exclusion criteria

Exclusion criteria: 1. who have the history of the allergy to this drug or related compounds 2. anuria (<100ml/day) 3. who do not feel thirst or who have difficulty in drinking 4. serum Na >145mEq/l 5. women who are pregnant or have the possibility of pregnancy

Design outcomes

Primary

Measure	Time frame
edema	—

Secondary

Measure	Time frame
change in urine volume (every day) change in body weight (day 8)	—

Countries

Japan

Contacts

Public ContactOHTAKE Takayasu

Shonan Kamakura General Hospital Dept. of Nephrology, Immunology and Vascular Medicine

ohtake@shonankamakura.or.jp0467-46-1717

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026